A share price of Standard BioTools Inc [LAB] is currently trading at $1.84, up 1.10%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LAB shares have gain 13.58% over the last week, with a monthly amount drifted -2.13%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Standard BioTools Inc [NASDAQ: LAB] stock has seen the most recent analyst activity on April 16, 2024, when TD Cowen initiated its Buy rating and assigned the stock a price target of $3.50. Previously, Jefferies started tracking the stock with Buy rating on April 04, 2024, and set its price target to $3.25. On July 12, 2023, KeyBanc Capital Markets initiated with a Overweight rating and assigned a price target of $4 on the stock.
Standard BioTools Inc experienced fluctuations in its stock price throughout the past year between $1.21 and $3.04. Currently, Wall Street analysts expect the stock to reach $3.25 within the next 12 months. Standard BioTools Inc [NASDAQ: LAB] shares were valued at $1.84 at the most recent close of the market. An investor can expect a potential return of 76.63% based on the average LAB price forecast.
Analyzing the LAB fundamentals
Trailing Twelve Months sales for Standard BioTools Inc [NASDAQ:LAB] were 155.90M which represents 77.27% growth. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at -0.82%, Pretax Profit Margin comes in at -0.8%, and Net Profit Margin reading is -0.8%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.29 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8067 points at the first support level, and at 1.7733 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8667, and for the 2nd resistance point, it is at 1.8933.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Standard BioTools Inc [NASDAQ:LAB] is 3.76. Further, the Quick Ratio stands at 3.41, while the Cash Ratio is 1.75. Considering the valuation of this stock, the price to sales ratio is 4.44, the price to book ratio is 1.40.
Transactions by insiders
Recent insider trading involved Black Jeffrey G., Former Officer, that happened on Nov 12 ’24 when 57971.0 shares were purchased. Former Officer, Taich Adam completed a deal on Sep 09 ’24 to buy 45851.0 shares. Meanwhile, Director Casdin Partners Master Fund, L bought 0.25 million shares on Aug 27 ’24.
